Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation
CompanyDrug

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation

CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the Phase Ib clinical trial of its self‑developed drug JMT206, for weight management in adult patients who are overweight or obese, has…

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

Jiangsu Nhwa Signs Exclusive Global Licensing Deal with Somnivera – Clinical‑Stage Sleep‑Disorder Asset Backed by Up to US$517.5 Million in Potential Value

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

MindRank Signs Exclusive Greater China Commercialization Deal With Sunshine Mandi for MDR‑001 – AI‑Designed Oral GLP‑1 Candidate in Phase III for Obesity, Worth Up to RMB 1.75 Billion

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Akeso Receives First $300M Installment from Summit for Bispecific Antibody Ivonescimab

CompanyDrug

InnoCare’s Gunagratinib Shows Promising Data in Cholangiocarcinoma at ASCO-GI 2023

CompanyDrug

Simcere’s Cosela Receives First Prescription in China for CDK4/6 Inhibition

CompanyDrug

Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer

CompanyDeals

HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development

CompanyDrug

Legend Biotech’s Carvykti Meets Primary Endpoint in CARTITUDE-4 Phase III Study

CompanyDrug

BeiGene’s Brukinsa Approved by FDA for Chronic Lymphocytic Leukemia

CompanyDrug

BMS’s Opdivo Approved in China for Neoadjuvant Therapy in Urothelial Carcinoma

Show More